MedTrace Logo

Memantine Augmentation in Obsessive-Compulsive Disorder

NCT00264238 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-05-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

Conditions

  • Obsessive-Compulsive Disorder

Interventions

DRUG

Memantine

pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder

Sponsors & Collaborators

Principal Investigators

  • John J Barry, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00264238 on ClinicalTrials.gov